Now in its 6th year, World ADC Berlin is the industry’s definitive conference for sharing new antibody drug conjugate insights and data. Thought leaders from Pfizer, MedImmune, Genentech, Merck and 40+ others will divulge unpublished, never seen before ADC drug research.Over 3 days, 60+ sessions will cover every aspect of ADC drug development from discovery, preclinical, clinical and marketisation giving you an unparalleled opportunity to gain insights and advance your ADC program. Make sure you keep pace with the latest advancements and develop the next generation of therapeutically successful ADCs. Join 300+ of your peers at next year’s definitive ADC learning forum and:Understand how Seattle Genetics developed high-DAR ADCs with superior in vivo performanceusing an innovative linker designEnhance chances of successful regulatory approval by hearing views from the FDAEffectively scale up from clinical to commercial manufacturing with four clinical case studies on building and maintaining a robust ADC manufacturing CMO network from PfizerSuccessfully develop warheads with different mechanisms of action with lesson learned from PBDs at SpirogenOvercome serum stability issues associated with thiol linked antibody drug conjugates using N-alkyl maleimides from MedImmuneIdentify novel ADC targets which have improved internalisation at a higher frequency with insight from GenmabImprove understanding of IgG limitations and discover validated alternative antibody formatswith RocheImprove pharmacokinetic understanding using cutting edge analytical and bioanalytical characterisation approaches from Pierre-FabreMaximise the ADC drug therapeutic window by learning how to effectively manage off-target toxicities with BayerDigest the latest clinical outcomes by reviewing results for the IMMU-132 Phase II for solid cancers which have had multiple prior therapies from Immunomedics